Matrix metalloproteinases

https://doi.org/10.1016/S1367-5931(98)80122-1Get rights and content

Abstract

Matrix metalloproteinases are a family of highly regulated peptidases that are collectively responsible for the degradation of extracellular matrix during tissue remodeling. Dysregulated activity has long been implicated in the pathologies of cancer and arthritis, and the number of diseases more recently associated with these enzymes has been increasing. In the past year, new transgenic models of matrix metalloproteinase knockouts have been described, allowing the direct assessment of specific enzyme activity in particular disease models. In addition, more selective inhibitors with improved pharmacokinetic profiles have entered clinical trials, allowing the assessment of the safety and efficacy of this strategy.

References (51)

  • V Dhanaraj et al.

    X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily

    Structure

    (1996)
  • H Rasmussen et al.

    Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat

    Pharmacol Ther

    (1997)
  • W Stetler-Stevenson

    Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix

    Am J Pathol

    (1996)
  • J Reynolds et al.

    The functional balance of metalloproteinases and inhibitors in tissue degradation: relevance to oral pathologies

    J R Coll Surg Edinb

    (1997)
  • C Dollery et al.

    Matrix metalloproteinases and cardiovascular disease

    Circ Res

    (1995)
  • A White et al.

    Emerging therapeutic advances for the development of second generation matrix metalloproteinas inhibitors

    Curr Pharm Des

    (1997)
  • H Nagase

    Matrix metalloproteinases

  • H Nagase

    Activation mechanisms of matrix metalloproteinases (of outstanding interest)

    Biol Chem

    (1997)
  • H Sato et al.

    Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion

    Thromb Haemost

    (1997)
  • H Sato et al.

    A matrix metalloproteinase expressed on the surface of invasive tumour cells

    Nature

    (1994)
  • H Nakahara et al.

    Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion

    Proc Natl Acad Sci USA

    (1997)
  • T Sato et al.

    Identification of the membrane-type matrix metalloproteinase MT1-MMP in osteoclasts

    J Cell Sci

    (1997)
  • C Wilson et al.

    Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin (of special interest)

    Proc Natl Acad Sci USA

    (1997)
  • R Hautamaki et al.

    Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice (of special interest)

    Science

    (1997)
  • J Mudgett et al.

    Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction

    Arthritis Rheum

    (1998)
  • Cited by (263)

    • CDH17 alters MMP-2 expression via canonical NF-κB signalling in human gastric cancer

      2019, Gene
      Citation Excerpt :

      Therefore, we suggest that abnormal CDH17 expression plays a key role in the malignancy-associated biological behaviours of AGS cells. MMPs constitute an enzyme family whose members require the presence of a zinc ion at the active site for catalytic activity, and these enzymes are critical for the maintenance of tissue allostasis (Pagemccaw et al., 2007; Parsons et al., 1998). Several MMPs, particularly MMP-2 and MMP-9, are presumably important in angiogenesis (Belotti et al., 2003; Werb, 2010).

    View all citing articles on Scopus
    View full text